Patients With Type 2 Diabetes and CKD Face Poor COVID Outcomes
(MedPage Today) -- SAN DIEGO -- Certain factors were highly predictive of severe COVID illness in hospitalized patients who had type 2 diabetes (T2D) and chronic kidney disease (CKD), a researcher reported. In a single-center study of patients... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 15, 2022 Category: Cardiology Source Type: news

Potassium Abnormalities Boost Hospital Visits for Kidney Disease Potassium Abnormalities Boost Hospital Visits for Kidney Disease
Patients with advanced chronic kidney disease who have hyper- or hypokalemia are at higher risk for ER visits and hospitalization, especially those with high potassium levels.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news

US Food and Drug Administration Accepts New Drug Application for Daprodustat
Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 19, 2022 Category: Drugs & Pharmacology Source Type: news

Does vitamin D have an effect on osseointegration of dental implants? A systematic review
ConclusionsVitamin D deficiency seems to have a negative effect on the osseointegration of implants in animals. The supplementation of vitamin D appears to improve the osseointegration in animals with systemic diseases, such as vitamin D deficiency, diabetes mellitus, osteoporosis, and CKD. Slight evidence supports the hypothesis that humans similarly benefit from vitamin D supplementation in terms of osseointegration. Further investigation is required to maintain these assumptions. (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 19, 2022 Category: Dentistry Source Type: news

Even With CKD, Patiromer Helped Heart Failure Patients Keep Hyperkalemia at Bay
(MedPage Today) -- Regardless of chronic kidney disease (CKD) stage, the potassium-binding agent patiromer (Veltassa) improved serum potassium levels in patients with heart failure, according to a prespecified CKD subanalysis from the DIAMOND trial... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 9, 2022 Category: Cardiology Source Type: news

New Instrument Developed for Assessing Patient Knowledge of CKD
MONDAY, April 4, 2022 -- The Knowledge Assessment of Renal Transplantation (KART) 2.0 instrument is valid for assessing patients ' knowledge of chronic kidney disease (CKD) and kidney transplantation, according to a study published online March 24 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2022 Category: Pharmaceuticals Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients
CAMBRIDGE, Mass., March 30, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 30, 2022 Category: Drugs & Pharmacology Source Type: news

NICE indicators consultation open
NICE has announced that the indicators for epilepsy, cardiovascular disease, chronic kidney disease and diabetes consultation is open. (Source: NHS Networks)
Source: NHS Networks - March 23, 2022 Category: UK Health Source Type: news

Elobixibat Improves Constipation in Chronic Kidney Disease
MONDAY, March 21, 2022 -- For patients with moderate- to end-stage chronic kidney disease, elobixibat is associated with improvement in constipation and lipid metabolism, according to a study recently published in Frontiers in Medicine. Momoko... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2022 Category: Pharmaceuticals Source Type: news

High LDL-C Bad for CAD but Good for CKD? Optimal Range Proposed High LDL-C Bad for CAD but Good for CKD? Optimal Range Proposed
Elevated LDL cholesterol cut the risk for chronic kidney disease, worsened the risk for cardiovascular disease, and had little effect on mortality in the context of a Mendelian randomization study.First Look (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 17, 2022 Category: Neurology Tags: Cardiology News Source Type: news

Study: Advanced kidney disease patients can survive, with quality life, without dialysis
People with advanced chronic kidney disease who decide against maintenance dialysis treatment still can survive for many years,with a high quality of life, an analysis published Monday by JAMA Network Open found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 14, 2022 Category: Consumer Health News Source Type: news

Does accepted definition of Clostridioides difficile infection (CDI) severity predict poor outcomes in older adults?
Background: Advanced age is an important factor affecting Clostridioides difficile infection (CDI) risk and outcome. While fever and leukocytosis are prominent findings in young individuals with CDI, they are usually blunted in the elderly. Furthermore, chronic kidney disease often exists among this population prior to the CDI episode onset. Aim: We aimed to examine whether the accepted definition of severe CDI (leukocytosis ≥ 15,000 cells/μl or serum creatinine> 1.5 mg/dl) predicts poor outcomes in the elderly. Methods: All CDI hospitalized individuals between January-2013 and May-2020 were included. The study popula...
Source: Current Awareness Service for Health (CASH) - March 14, 2022 Category: Consumer Health News Source Type: news

Penn Medicine targets chronic kidney disease care with new joint venture
"We need to take a new approach to caring for kidney disease patients." (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 11, 2022 Category: Health Management Authors: John George Source Type: news

Community Genetic Testing Prompts Behavior Change in Patients Community Genetic Testing Prompts Behavior Change in Patients
Test results for kidney failure risk prompt positive behavior change in patients and providers that might offset risk of developing chronic kidney disease and end-stage renal failure later in life.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 9, 2022 Category: Transplant Surgery Tags: Nephrology News Source Type: news